Semaglutide alters NAc oscillations in mice

A study published in Molecular Brain on 11 July 2026 reports that semaglutide alters reward-related behaviour and changes oscillatory patterns in the nucleus accumbens (NAc) of healthy mice^[1]. The finding is notable because almost all prior work on semaglutide's brain effects has been conducted in rodent models of obesity or metabolic disease. This paper asks what the drug does in a brain that is not already metabolically stressed.

What the study did

Alejo Mosqueira, Sanaz Ansarifar, Sadegh Nabavi, and Andrea Moreno at the Danish National Research Foundation (DNRF133) administered semaglutide daily at 0.1 mg/kg to healthy, non-obese mice and ran a battery of behavioural tests alongside acute neurophysiological recordings from the NAc^[1]. The nucleus accumbens sits at the intersection of the brain's reward and motivation circuits. It receives dopamine input from the ventral tegmental area, integrates signals about food, drug rewards, and stress, and is one of the most studied structures in addiction and compulsive-eating research^[6].

Using local field potential (LFP) recordings, the team measured oscillatory activity in the delta, theta, and alpha frequency bands. These oscillations reflect the rhythmic firing of large neuron populations and serve as markers of circuit-level engagement. Prior rodent work on GLP-1 class drugs had focused mainly on hypothalamic satiety circuits, making the NAc recording focus here distinctive^[1].

What they found

The authors report two main findings. First, daily semaglutide altered behaviour across tests related to stress and reward pursuit in the healthy mice. The paper describes these as alterations without framing them as beneficial or harmful, leaving interpretation open while the underlying mechanisms are characterised. Second, an acute dose changed oscillatory activity in the NAc across the delta, theta, and alpha bands^[1].

The authors conclude that semaglutide "impacts both behaviour and neural dynamics in non-diseased brains." That framing extends the conversation about GLP-1 receptor agonist brain effects beyond appetite suppression and away from the assumption that those effects are exclusively tied to metabolic disease^[1].

The prior evidence this paper extends

This is not the first time semaglutide has shown activity in reward-related brain circuits in rodents. Aranäs and colleagues (EBioMedicine, 2023) showed that fluorescently labelled semaglutide accumulates in the NAc and blocks the dopamine elevation that alcohol produces there^[2]. A follow-up from the same group (European Neuropsychopharmacology, 2025) found that semaglutide attenuates cocaine-evoked NAc dopamine spikes and reduces cocaine self-administration in rats^[3].

A 2025 preprint from Yale University (Foscue et al.) reported that semaglutide suppresses voluntary wheel running in lean and obese mice, independently of reduced food intake, and that real-time fiber photometry detected altered dopamine dynamics in the NAc during running^[4]. A 2026 systematic review of 41 preclinical and clinical studies (Völker et al., Frontiers in Pharmacology) concluded that GLP-1 receptor agonists reduce substance intake and cue-triggered drug-seeking across several drug classes, acting through mesolimbic dopamine suppression^[5]. The Mosqueira paper adds a healthy-brain data point to this line: the NAc effects are not limited to disease states.

What this is not

This is a mouse study. The doses used (0.1 mg/kg daily) are research doses in mice; the human therapeutic doses dispensed as Ozempic and Wegovy have different pharmacokinetic profiles, and translating mouse dosing to human equivalents is not straightforward. No human participants were involved. The study does not demonstrate that semaglutide causes any specific neurological or psychiatric outcome in people, and the authors do not claim it does^[1].

The paper also does not say whether the oscillatory changes are adaptive, harmful, or neutral over time. That requires longitudinal recordings the study did not provide. The contribution is a baseline: measurable NAc effects in a non-diseased preparation. For the full evidence picture on semaglutide's approved uses and safety profile, see our semaglutide overview page.

The open question this paper belongs to

Tens of millions of people now take GLP-1 receptor agonists for obesity and type-2 diabetes. A growing part of the research community is asking what long-term exposure to these drugs does to the brain's reward architecture, particularly in people who do not have the metabolic disease that most preclinical models replicate. The Mosqueira et al. paper is a step in that direction. It does not answer the clinical question, but it establishes that the NAc signal exists in healthy brains worth tracking systematically^[1].

For the clinical side of that debate, a 2025 Penn Medicine case study recorded NAc activity in a single human patient on tirzepatide and found that food-craving suppression attenuated at five months. These rodent LFP data and that human case study are asking compatible questions from different angles. What neither paper settles is how these signals play out in people on GLP-1 class drugs over years of continuous therapy. That question is still open. If you are taking semaglutide and have questions about how it may be affecting your motivation or appetite beyond weight, that conversation belongs with your prescriber.